Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Maximizing the use of a first clinically viable MYC inhibitor

Descripción del proyecto

El oncogén MYC como objetivo

Los MYC son una familia de genes reguladores y protooncogenes que desempeñan papeles cruciales en la progresión del ciclo celular, la apoptosis y la transformación celular. La sobreexpresión o amplificación del MYC se observa en muchos tipos de cáncer, lo que produce una proliferación celular descontrolada y el desarrollo de tumores. Aunque los genes MYC son dianas importantes para la intervención terapéutica, ningún inhibidor de MYC ha alcanzado la aprobación clínica. Financiado por el Consejo Europeo de Investigación, el equipo del proyecto MYCiMAX se centra en la Omomyc, la primera miniproteína inhibidora del MYC que completa un ensayo clínico de fase I. Los investigadores explorarán la eficacia de la Omomyc en neoplasias encefálicas y la combinarán con otros inhibidores para estudiar el papel del MYC en la respuesta al daño del ADN y la cooperación entre los oncogenes.

Objetivo

Even though the MYC oncogene is a “most-wanted” target in cancer therapy, no MYC inhibitor has yet reached clinical approval. The applicant has developed Omomyc, the first MYC-inhibiting mini-protein to have successfully completed a Phase Ia clinical trial. The goal of this proposal is to maximise the use of this compound, as both a therapeutic and study tool, opening new lines of research in different aspects of MYC biology.
To start with, since Omomyc cannot efficiently cross the blood brain barrier, excluding it from use in brain malignancies or brain metastases, in Aim 1, we propose to validate its efficacy when delivered intracranially by different means, including osmotic pumps and hydrogels, as well as to test its delivery by intracarotid injection, in glioblastoma and brain metastases.
Then, in Aim 2 and 3, we will explore its combination with personalized medicine, namely PARPi and KRASi, respectively. These 2 aims are derived from two pillars of MYC biology: its role in DNA damage response and the paradigm of oncogene cooperation. Aim 2 will allow us to shed light on the role of MYC in homologous recombination and resistance to PARPi, while Aim 3 will deliver on the molecular mechanisms underlying the cooperation of RAS and MYC in multiple tumour types, where their combined inhibition could represent an unprecedented therapeutic opportunity.
Finally, Aim 4 will focus on the characterisation of cancers such as Small Cell Lung Cancer and Gastrointestinal Stromal Tumours that have the peculiarity of being defective for MAX – MYC’s natural partner – but that recapitulate a MYC-dependent tumour phenotype, likely driven by other members of the MYC network, whose function could also be hindered by Omomyc treatment.
Notably, each of the aims explores new aspects of MYC biology, tracing new lines of research around the most deregulated oncogene in human tumours as well as having immediate translational applicability in upcoming clinical trials of Omomyc.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC - HORIZON ERC Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2023-ADG

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Aportación neta de la UEn
€ 2 499 904,00
Coste total
€ 2 499 904,00

Beneficiarios (1)